Mutations in other genes of this pathway (e.g., LEPR , POMC ) also cause monogenic obesity, but the efficacy of bariatric surgery in these patients differs from that in MC4R -deficient patients
About the study In the present study, researchers developed and validated an estimation model to provide individualized estimates of differences in one-year glycemic outcomes for GLP1-receptor agonists and SGLT2-inhibitors
See how science, strategy, and innovation are transforming the GLP-1 space: #GLP1 #oralGLP1 #metabolichealth #diabetescare #obesity #obesitytreatment #pharmainnovation #futureproofingbusinesses #IeB To view or add a comment, sign in #MIMSPharmaMarketInsightUpdate, September 2025 Including: SGLT2 inhibitors should be offered first-line to people with heart failure with reduced ejection fraction A new formulation of Rybelsus (semaglutide) tablets has been released The first inhaled levodopa product, Inbrija (levodopa), has been launched
Over the years, or as a result of disease, the natural production of glutathione in the liver decreases
There is also the food factor
They reported reduced drive to eat, in addition to less physical hunger
)
